Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
McKesson
Dow
Moodys
McKinsey

Last Updated: December 3, 2022

CLINICAL TRIALS PROFILE FOR GEFITINIB


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


505(b)(2) Clinical Trials for Gefitinib

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Combination NCT02353741 ↗ Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLC Terminated Xinqiao Hospital of Chongqing Phase 2 2015-04-01 This single-arm phase II study aims to study the efficacy of a possible first line treatment that combines epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) with concurrent thoracic radiation therapy for stage IV non-small cell lung cancer (NSCLC) with active EGFR mutation, as well as assessing PFS, OS, tumor response, etc. to verify that this new combinational therapy can benefit short-term and long-term survival of the patients with advanced NSCLC.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Gefitinib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00005806 ↗ Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed National Cancer Institute (NCI) Phase 1 1999-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy in treating patients who have advanced non-small cell lung cancer.
NCT00005806 ↗ Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed Memorial Sloan Kettering Cancer Center Phase 1 1999-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy in treating patients who have advanced non-small cell lung cancer.
NCT00006048 ↗ ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer Unknown status AstraZeneca Phase 3 2000-05-01 RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep growing. ZD 1839 may interfere with the growth factor and stop the tumor from growing. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether chemotherapy is more effective with or without ZD 1839 for non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without ZD 1839 in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
NCT00006049 ↗ ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer Unknown status AstraZeneca Phase 3 2000-05-01 RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep growing. ZD 1839 may interfere with the growth factor and stop the tumor from growing. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether combination chemotherapy is more effective with or without ZD 1839 for non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without ZD 1839 in treating patients who have stage III or stage IV non-small cell lung cancer.
NCT00012337 ↗ ZD 1839 in Treating Patients With Metastatic Kidney Cancer Completed National Cancer Institute (NCI) Phase 2 2001-01-01 RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep growing. Drugs such as ZD 1839 may interfere with the growth factors and cause tumor cells to die. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have metastatic kidney cancer.
NCT00012337 ↗ ZD 1839 in Treating Patients With Metastatic Kidney Cancer Completed Memorial Sloan Kettering Cancer Center Phase 2 2001-01-01 RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep growing. Drugs such as ZD 1839 may interfere with the growth factors and cause tumor cells to die. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have metastatic kidney cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Gefitinib

Condition Name

Condition Name for Gefitinib
Intervention Trials
Non-small Cell Lung Cancer 55
Lung Cancer 39
Non Small Cell Lung Cancer 24
Carcinoma, Non-Small-Cell Lung 19
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Gefitinib
Intervention Trials
Carcinoma, Non-Small-Cell Lung 202
Lung Neoplasms 169
Adenocarcinoma 29
Carcinoma 25
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Gefitinib

Trials by Country

Trials by Country for Gefitinib
Location Trials
United States 515
China 167
Japan 92
Italy 88
Korea, Republic of 87
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Gefitinib
Location Trials
New York 40
Texas 33
California 30
Massachusetts 28
Pennsylvania 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Gefitinib

Clinical Trial Phase

Clinical Trial Phase for Gefitinib
Clinical Trial Phase Trials
Phase 4 11
Phase 3 53
Phase 2/Phase 3 9
[disabled in preview] 291
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Gefitinib
Clinical Trial Phase Trials
Completed 202
Unknown status 76
Terminated 36
[disabled in preview] 58
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Gefitinib

Sponsor Name

Sponsor Name for Gefitinib
Sponsor Trials
AstraZeneca 91
National Cancer Institute (NCI) 65
Sun Yat-sen University 13
[disabled in preview] 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Gefitinib
Sponsor Trials
Other 421
Industry 196
NIH 68
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
McKinsey
Colorcon
McKesson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.